Technical Analysis for AVXL - Anavex Life Sciences Corp.

Grade Last Price % Change Price Change
D 11.14 2.48% 0.27
AVXL closed up 2.48 percent on Tuesday, May 11, 2021, on 52 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 13
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical AVXL trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -3.72%
Wide Bands Range Expansion -3.21%
Older End-of-Day Signals for AVXL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 15 hours ago
Outside Day about 15 hours ago
Up 3% about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 2% about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Anavex Life Sciences Corp. Description

Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Cancers Chemical Compounds Neuroscience Alzheimer's Disease Alzheimer's Central Nervous System Disease Central Nervous System Diseases Piperidines Treatment Of Alzheimer's Disease Lewy Body Dementia Neuroprotection Donepezil Nootropics

Is AVXL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.6799
52 Week Low 3.42
Average Volume 1,330,148
200-Day Moving Average 7.78
50-Day Moving Average 13.26
20-Day Moving Average 11.86
10-Day Moving Average 11.71
Average True Range 0.75
ADX 27.34
+DI 11.69
-DI 29.65
Chandelier Exit (Long, 3 ATRs ) 12.49
Chandelier Exit (Short, 3 ATRs ) 12.59
Upper Bollinger Band 12.82
Lower Bollinger Band 10.90
Percent B (%b) 0.12
BandWidth 16.17
MACD Line -0.57
MACD Signal Line -0.49
MACD Histogram -0.0755
Fundamentals Value
Market Cap 670.52 Million
Num Shares 60.2 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -18.63
Price-to-Sales 0.00
Price-to-Book 12.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.63
Resistance 3 (R3) 12.52 11.92 12.38
Resistance 2 (R2) 11.92 11.54 11.97 12.30
Resistance 1 (R1) 11.53 11.31 11.73 11.64 12.21
Pivot Point 10.93 10.93 11.03 10.98 10.93
Support 1 (S1) 10.54 10.55 10.74 10.64 10.07
Support 2 (S2) 9.94 10.32 9.99 9.98
Support 3 (S3) 9.55 9.94 9.90
Support 4 (S4) 9.65